AbbVie | ABBV - Selling And Administration Expenses


AbbVie reported $3.63B in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.63B 54M Jun/2026
Abbott USD 3.6B 330M Jun/2026
ALKERMES USD 196.64M 67.96M Jun/2026
Amgen USD 1.58B 354M Mar/2026
AstraZeneca USD 5.8B 735M Jun/2026
Biogen USD 709.7M 155.4M Jun/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Coherus Biosciences USD 15M 6.26M Dec/2025
Eisai JPY 114.83B 4.71B Jun/2026
Eli Lilly USD 2.93B 198M Mar/2026
Gilead Sciences USD 1.45B 326M Mar/2026
GlaxoSmithKline GBP 2.19B 75M Jun/2026
J&J USD 6.42B 381M Jun/2026
Medtronic 2.96B 9M Dec/2025
Merck USD 2.67B 180M Mar/2026
Neurocrine Biosciences USD 383.1M 64.6M Jun/2026
Novartis USD 3.24B 101M Jun/2026
Pacira USD 83.88M 7.99M Mar/2026
Perrigo USD 267.3M 11.4M Mar/2026
Pfizer USD 3.41B 496M Jun/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sanofi EUR 2.63B 307M Jun/2026
UCB EUR 1.47B 193M Dec/2025
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
United Therapeutics USD 156.6M 34M Mar/2026
Vertex Pharmaceuticals USD 582.2M 88.5M Jun/2026
Zoetis USD 588M 31M Mar/2026